Rick discusses the groundbreaking work being done with MDMA-assisted psychotherapy for PTSD, highlighting its designation as a breakthrough therapy by the FDA. He shares insights into the extensive research and funding efforts behind the nonprofit drug development initiative, emphasizing the importance of upcoming phase three study results. The potential impact of these findings could lead to FDA approval as early as 2022, marking a significant milestone in mental health treatment.
